Kinhely

Kinhely Bio-Tech Co., Ltd., established in 2007 in Shenzhen, the innovation capital of China; as an innovative enterprise supported by the Shenzhen Development and Reform Commission, it is dedicated to the research and development, production, sales, and technical services in the field of cardiovascular interventional therapy. Relying on the National Key Basic Research Development Program (973 Program), the company designed the world's first-of-its-kind "Titanium-Oxygen Coating-Free Cobalt-Based Alloy Drug-Eluting Stent System"; and designed and implemented the first prospective, multi-center, randomized controlled registration clinical trial in China. The HELIOS sirolimus drug-eluting stent received SFDA approval for marketing on December 26, 2011. In October 2013, the company was awarded the title of National High-Tech Enterprise. The company will focus on the field of cardiovascular intervention, providing advanced treatment solutions for clinical use, alleviating patients' suffering, helping employees realize personal value, and contributing to society.